A Randomized, Double-blind, Placebo-controlled Phase 2 Study of TG103 Injection in the Management of Non-diabetic Overweight or Obesity
Latest Information Update: 21 May 2025
At a glance
- Drugs GX G6 (Primary)
- Indications Obesity
- Focus Therapeutic Use
- Sponsors CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Most Recent Events
- 14 May 2025 Status changed from active, no longer recruiting to completed.
- 16 Jul 2024 Planned primary completion date changed from 20 Dec 2024 to 31 Dec 2024.
- 16 Jul 2024 Status changed from not yet recruiting to active, no longer recruiting.